Global Blood Therapeutics to seek to expand label for sickle cell treatment

Global Blood Therapeutics Inc said on Monday it plans to ask U.S. regulators to greenlight the use of its sickle cell treatment, Oxbryta, in children aged 4 to 11, expanding on an earlier approval for patients 12 and over.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news